Top

BMC Oral Health

Published in:

Open Access 01-12-2021 | Lichen Planus | Research

Serum 8-isoprostane levels in patients with resistant oral lichen planus before and after treatment with lycopene: a randomized clinical trial

Authors: Aliaa Abdelmoniem Bedeir Eita, Azza Mohamed Zaki, Sabah Abdelhady Mahmoud

Published in: BMC Oral Health | Issue 1/2021

Abstract

Background

Oral lichen planus is an autoimmune disease in which topical steroids are the first line of treatment. The adverse effects of systemic corticosteroids prescribed for resistant oral lichen planus cases advocate alternative modalities. Lycopene is an antioxidant with a wide range of beneficial properties. This trial aimed to evaluate the effect of pure lycopene as compared to systemic corticosteroids (Prednisolone) on the symptoms, signs and oxidative stress in patients with erosive oral lichen planus recalcitrant to topical steroids.

Methods

Twenty patients were randomly divided into the test (lycopene) and control (corticosteroids) groups. Numeric rating scale and Escudier et al. (Br J Dermatol 4:765–770, 2007. https://doi.org/10.1111/j.1365-2133.2007.08106.x) lesion scores were assessed at baseline and weeks 4 and 8 from baseline. Serum levels of 8-isoprostane were measured in all patients at baseline and at the end of treatment (week 8).

Results

There was a significant reduction in signs and symptoms after the end of treatment in each group. However, no significant difference was found between the lycopene and the corticosteroids group. Moreover, a significant reduction in 8-isoprostane levels was observed in the lycopene group from baseline and as compared to the control group.

Conclusions

Based on the study results, lycopene is a safe and effective therapeutic modality for resistant oral lichen planus. 8-isoprostane is a biomarker of lipid peroxidation that can be reduced by lycopene.

Trial registration ID: PACTR202003484099670. 'Retrospectively registered on 11/3/2020'.

Available only for authorised users

Canto AM, Müller H, Freitas RR, Santos PS. Oral lichen planus (OLP): clinical and complementary diagnosis. An Bras Dermatol. 2010;85:669–75. https://doi.org/10.1590/s0365-05962010000500010.CrossRefPubMed

Walton KE, Bowers EV, Drolet BA, Holland KE. Childhood lichen planus: demographics of a U.S. population. Pediatr Dermatol. 2020;27:34–8. https://doi.org/10.1111/j.1525-1470.2009.01072.x.CrossRef

Park SY, Lee HJ, Kim SH, Kim SB, Choi YH, Kim YK, et al. Factors affecting treatment outcomes in patients with oral lichen planus lesions: a retrospective study of 113. J Periodontal Implant Sci. 2018;48:213–23. https://doi.org/10.5051/jpis.2018.48.4.213.CrossRefPubMedPubMedCentral

Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev. 2011. https://doi.org/10.1002/14651858.CD001168.pub2.CrossRefPubMed

Wang K, Miao T, Lu W, He J, Cui B, Li J, et al. Analysis of oral microbial community and Th17-associated cytokines in saliva of patients with oral lichen planus. Microbiol Immunol. 2015;59:105–13. https://doi.org/10.1111/1348-0421.12232.CrossRefPubMed

Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What’s new. J Eur Acad Dermatol Venereol. 2003;17:663–9. https://doi.org/10.1046/j.1468-3083.2003.00751.x.CrossRefPubMed

Kushwaha RP, Rauniar GP, Rimal J. Comparative study of the efficacy of lycopene versus prednisolone in the management of oral lichen planus—a randomized, double blind clinical trial. World J Pharm Pharm Sci. 2017;6:1103–15. https://doi.org/10.20959/wjpps20175-9144.CrossRef

Alvarado A, Arce I. Antioxidants in respiratory diseases: basic science research and therapeutic alternatives. Clin Res Trials. 2016;3:1–11. https://doi.org/10.15761/CRT.1000163.CrossRef

Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757–72. https://doi.org/10.2147/CIA.S158513.CrossRefPubMedPubMedCentral

10.

Rekha VR, Sunil S, Rathy R. Evaluation of oxidative stress markers in oral lichen planus. J Oral Maxillofac Pathol. 2017;21:387–93. https://doi.org/10.4103/jomfp.JOMFP_19_17.CrossRefPubMedPubMedCentral

11.

Amirchaghmaghi M, Hashemy SI, Alirezaei B, Keyhani FJ, Kargozar S, Vasigh S, et al. Evaluation of plasma isoprostane in patients with oral lichen planus. J Dent (Shiraz). 2016;17:21–5.

12.

van’t Erve TJ, Kadiiska MB, London SJ, Mason RP. Classifying oxidative stress by F₂-isoprostane levels across human diseases: a meta-analysis. Redox Biol. 2017;12:582–99. https://doi.org/10.1016/j.redox.2017.03.024.CrossRef

13.

Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl 25:1–12. https://doi.org/10.1016/j.tripleo.2006.11.001.CrossRef

14.

Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63:655–70. https://doi.org/10.4187/respcare.06314.CrossRefPubMed

15.

Dasgupta A, Klein K. Herbal and other dietary supplements that are antioxidants. In: Dasgupta A, Klein K, editors. Antioxidants in food, vitamins and supplements, 1st edn. Amsterdam, Boston: Elsevier; 2014. p. 295–315

16.

Gupta S, Jawanda MK, Arora V, Mehta N, Yadav V. Role of lycopene in preventing oral diseases as a nonsurgical aid of treatment. Int J Prev Med. 2015;6:70. https://doi.org/10.4103/2008-7802.162311.CrossRefPubMedPubMedCentral

17.

Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10:28–55.CrossRef

18.

Enomoto Y, Suzuki H, Kimoto A, Asai T, Takeuchi J, Matsumoto K, et al. Concordance between clinical and histopathological diagnoses of oral lichen planus. J Oral Maxillofac Surg Med Pathol. 2016;28:381–4. https://doi.org/10.1016/j.ajoms.2016.04.001.CrossRef

19.

Boorghani M, Gholizadeh N, Taghavi Zenouz A, Vatankhah M, Mehdipour M. Oral lichen planus: clinical features, etiology, treatment and management; a review of literature. J Dent Res Dent Clin Dent Prospects. 2010;4:3–9. https://doi.org/10.5681/joddd.2010.002.CrossRefPubMedPubMedCentral

20.

Malik U, Gupta S, Malik SD, Vashishth S, Raju MS. Treatment of symptomatic oral lichen planus (OLP) with 0.1% tacrolimus powder in Oraguard-B—a pilot prospective study. Saudi Dent J. 2012;24:143–8. https://doi.org/10.1016/j.sdentj.2012.05.002.CrossRefPubMedPubMedCentral

21.

Piñas L, García-García A, Pérez-Sayáns M, Suárez-Fernández R, Alkhraisat MH, Anitua E. The use of topical corticosteroides in the treatment of oral lichen planus in Spain: a national survey. Med Oral Patol Oral Cir Bucal. 2017;22:e264–9. https://doi.org/10.4317/medoral.21435.CrossRefPubMedPubMedCentral

22.

Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet. 2002;359:515–9.CrossRef

23.

Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359:614–8. https://doi.org/10.1016/S0140-6736(02)07750-4.CrossRef

24.

Karanicolas PJ, Farrokhyar F, Bhandari M. Blinding: who, what, when, why, how? Can J Surg. 2010;53:345–8.PubMedPubMedCentral

25.

Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G* Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149–60.CrossRef

26.

Hylown Consulting LLC. Power and Sample Size Calculator. In: power and sample size. 2013. http://powerandsamplesize.com/Calculators/Compare-2-Means/2-Sample-Equality. Accessed 1 Sept 2018.

27.

Chow SC, Shao J, Wang H. Sample size calculations in clinical research. 2nd ed. Boca Raton: CRC Press; 2018.

28.

Kaur G, Sandal A, Dhillon NS. Lycopene and human health—a review. Agric Rev. 2017;38:282–9.

29.

Kini R, Nagaratna DV, Saha A, Praveen BN. Therapeutic management of oral lichen planus: a review for the clinicians. World J Dent. 2011;2:249–53. https://doi.org/10.5005/jp-journals-10015-1091.CrossRef

30.

Salgado DS, Jeremias F, Capela MV, Onofre MA, Massucato EM, Orrico SR. Plaque control improves the painful symptoms of oral lichen planus gingival lesions. A short-term study. J Oral Pathol Med. 2013;42:728–32. https://doi.org/10.1111/jop.12093.CrossRefPubMed

31.

World Health Organization. WHO guidelines on drawing blood: best practices in phlebotomy. World Health Organization. 2010. https://www.euro.who.int/__data/assets/pdf_file/0005/268790/WHO-guidelines-on-drawing-blood-best-practices-in-phlebotomy-Eng.pdf?ua=1. Accessed 25 Aug 2018.

32.

Roberts LJ II, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28:505–13. https://doi.org/10.1016/s0891-5849(99)00264-6.CrossRefPubMed

33.

Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol. 2002;46:35–41. https://doi.org/10.1067/mjd.2002.120535.CrossRefPubMed

34.

Escudier M, Ahmed N, Shirlaw P, Setterfield J, Tappuni A, Black MM, et al. A scoring system for mucosal disease severity with special reference to oral lichen planus. Br J Dermatol. 2007;4:765–70. https://doi.org/10.1111/j.1365-2133.2007.08106.x.CrossRef

35.

Petrie A, Sabin C. Medical statistics at a glance. 2nd ed. West Sussex: Wiley; 2009.

36.

Schlosser BJ. Lichen planus and lichenoid reactions of the oral mucosa. Dermatol Ther. 2010;23:251–67. https://doi.org/10.1111/j.1529-8019.2010.01322.x.CrossRefPubMed

37.

Saawarn N, Shashikanth MC, Saawarn S, Jirge V, Chaitanya NC, Pinakapani R. Lycopene in the management of oral lichen planus: a placebo-controlled study. Indian J Dent Res. 2011;22:639–43. https://doi.org/10.4103/0970-9290.93448.CrossRefPubMed

38.

Shekhawat KS, Deepak TA, Srivastava C. Assessment of lycopene and levamisole in management of oral lichen planus—a comparative study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;2:4–10.CrossRef

39.

Arbabi-Kalati F, Farahmand MM. Evaluation of the efficacy of lycopene in the management of oral lichen planus: a pilot randomized clinical trial. Tehran Univ Med J. 2017;75:658–62.

40.

Hazzaa HH, Elsaadany B, Ahmed EM, Ali SAM, Abdulhady EM. Oral lycopene effect on the salivary malondialdehyde levels in symptomatic oral lichen planus patients: clinical and biochemical study. J Oral Health Dent. 2020;3:193–200.

41.

Carbone M, Goss E, Carrozzo M, Castellano S, Conrotto D, Broccoletti R, et al. Systemic and topical corticosteroid treatment of oral lichen planus: a comparative study with long-term follow-up. J Oral Pathol Med. 2003;32:323–9.CrossRef

42.

Radwan-Oczko M. Topical application of drugs used in treatment of oral lichen planus lesions. Adv Clin Exp Med. 2013;22:893–8. https://doi.org/10.1034/j.1600-0714.2003.00173.x.CrossRefPubMed

43.

Selvam NP, Dayanand AA. Lycopene in the management of oral submucous fibrosis. Asian J Pharm Clin Res. 2013;6:58–61.

44.

Glaeser J, Nuss AM, Berghoff BA, Klug G. Singlet oxygen stress in microorganisms. Adv Microb Physiol. 2011;58:141–73.CrossRef

45.

Simone RE, Russo M, Catalano A, Monego G, Froehlich K, Boehm V, et al. Lycopene inhibits NF-kB-mediated IL-8 expression and changes redox and PPARγ signalling in cigarette smoke–stimulated macrophages. PLoS ONE. 2016;6:e19652. https://doi.org/10.1371/journal.pone.0019652.CrossRef

46.

Cha JH, Kim WK, Ha AW, Kim MH, Chang MJ. Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells. Nutr Res Pract. 2017;11:90–6. https://doi.org/10.4162/nrp.2017.11.2.90.CrossRefPubMedPubMedCentral

47.

Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus—a review. J Oral Pathol Med. 2010;39:729–34. https://doi.org/10.1111/j.1600-0714.2010.00946.x.CrossRefPubMed

48.

Muzio LL, Della Valle A, Mignogna MD, Mignogna MD, Pannone G, Bucci P, et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. J Oral Pathol Med. 2001;30:611–7. https://doi.org/10.1034/j.1600-0714.2001.301006.x.CrossRefPubMed

49.

Mignogna MD, Fedele S, Lo Russo L, Mignogna C, de Rosa G, Porter SR. Field cancerization in oral lichen planus. Eur J Surg Oncol. 2007;33:383–9. https://doi.org/10.1016/j.ejso.2006.09.028.CrossRefPubMed

50.

Kaplan I, Ventura-Sharabi Y, Gal G, Calderon S, Anavi Y. The dynamics of oral lichen planus: a retrospective clinicopathological study. Head Neck Pathol. 2012;6:178–83. https://doi.org/10.1007/s12105-011-0318-3.CrossRefPubMed

51.

Visioli F, Riso P, Grande S, Galli C, Porrini M. Protective activity of tomato products on in vivo markers of lipid oxidation. Eur J Nutr. 2003;42:201–6. https://doi.org/10.1007/s00394-003-0415-5.CrossRefPubMed

52.

van’T Erve TJ, Lih FB, Kadiiska MB, Deterding LJ, Eling TE, Mason RP. Reinterpreting the best biomarker of oxidative stress: The 8-iso-PGF(2α)/PGF(2α) ratio distinguishes chemical from enzymatic lipid peroxidation. Free Radic Biol Med. 2015;83:245–51.CrossRef

53.

Suleyman H, Dursun H, Bilici M, Cadirci E, Halici Z, Gulaboglu M, Albayrak F. Relation of adrenergic receptors, which have roles in gastroprotective and anti-inflammatory effect of adrenal gland hormones, with cyclooxygenase enzyme levels in rats. J Physiol Pharmacol. 2009;60:129–34.PubMed

54.

Lin HY, Lin H, Lu DY. Lycopene inhibits cyclooxygenase-2 and inflammatory mediator expression in microglia. FASEB J. 2013;27:1168.3.

55.

Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax. 2005;60:827–33.CrossRef

Title: Serum 8-isoprostane levels in patients with resistant oral lichen planus before and after treatment with lycopene: a randomized clinical trial
Authors: Aliaa Abdelmoniem Bedeir Eita
Azza Mohamed Zaki
Sabah Abdelhady Mahmoud
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lichen Planus
Prednisolone
Published in: BMC Oral Health / Issue 1/2021
Electronic ISSN: 1472-6831
DOI: https://doi.org/10.1186/s12903-021-01711-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum 8-isoprostane levels in patients with resistant oral lichen planus before and after treatment with lycopene: a randomized clinical trial

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Oral health status and behaviors of pregnant migrant workers in Bangkok, Thailand: a cross-sectional study

Assessment of root morphology and canal configuration of maxillary premolars in a Saudi subpopulation: a cone-beam computed tomographic study

Comparison of the canal transportation of ProTaper GOLD, WaveOne GOLD, and TruNatomy in simulated double-curved canals

Influence of the type of reciprocating motion on the cyclic fatigue resistance of reciprocating files in a dynamic model

Oral health status of children and young adults with maple syrup urine disease in Turkey

Exploring the opinions of secondary school students on the strengths and weaknesses of the school dental service in Selangor, Malaysia: a qualitative study